LoadingLoadingLoading34 funds hold it.Insiders trading both ways.
No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Oct 30, 2026
Period ending
Sep 30, 2026
Earnings per share
$2.60 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Nov 7, 2026
EPS expected
$1.74 to $1.74
Revenue expected
13 analysts
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Oct 30, 2026 | $2.79est. $2.60 | +7.31%beat | $15.99BAlpha Vantage | +5.3%from $15.19B |
| Jun 30, 2026Reported Jul 27, 2026 | $1.31est. $1.25 | +4.85%beat | $15.38BSEC filing | +6.4%from $14.46B |
| Mar 31, 2026Reported Apr 29, 2026 | $1.29est. $1.27 | +1.43%beat | $15.29BAlpha Vantage | +12.5%from $13.59B |
| Dec 31, 2025Reported Feb 10, 2026 | $1.49Reported | No estimate | $15.50BAlpha Vantage | +4.1%from $14.89B |
| Sep 30, 2025Reported Nov 6, 2025 | $1.19est. $1.13 | +5.31%beat | $15.19BAlpha Vantage | +12.0%from $13.56B |
| Jun 30, 2025Reported Jul 29, 2025 | $0.79est. $0.88 | -10.23%miss | $14.46BSEC filing | +11.7%from $12.94B |
| Mar 31, 2025Reported Apr 29, 2025 | $1.25est. $1.12 | +11.61%beat | $13.59BAlpha Vantage | +7.2%from $12.68B |
| Dec 31, 2024Reported Feb 6, 2025 | $1.05est. $1.04 | +0.96%in line | $14.89BAlpha Vantage | +23.8%from $12.02B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $15.50B | $15.29B | $15.38B | $15.99B |
| Cost of what it sold | $3.12B | $2.68B | $2.52B | $4.06B |
| Gross profit | $12.38B | $12.61B | $12.86B | $11.93B |
| What it spent | ||||
| Research and development | $3.86B | $3.49B | $4.05B | $3.60B |
| Sales and admin | $5.49B | $4.92B | $5.65B | $5.11B |
| Other operating costs | — | — | — | -$1.09B |
| Total operating expenses | $9.41B | $8.36B | $9.70B | $7.61B |
| What was left | ||||
| Operating profit | $2.98B | $4.25B | $3.16B | $4.32B |
| Interest on debt | $472.0M | $393.0M | $435.0M | $470.6M |
| Profit before tax | $2.63B | $3.91B | $2.80B | $3.91B |
| Tax | $300.0M | $833.0M | $291.0M | $830.8M |
| Net profit | $2.33B | $3.08B | $2.51B | $3.08B |
| EBITDA | $4.63B | $5.67B | $5.16B | $5.90B |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
RYTM Stock Clocks Best Day In Nearly 16 Months On AstraZeneca $10B Bid Report
Leans bullishNov 4AstraZeneca Analyst Raises Price Target On Q3 Results, Shift In Avanzar Timing
Leans bullishNov 3REG - AstraZeneca PLC - Admission of Further Securities to Trading
NeutralNov 2Weekly Recap: Q3 revenue, oncology gains and three-year cost cuts
BullishNov 2AstraZeneca cans late-stage Ultomiris trial on lacklustre efficacy predictions
Leans bearishOct 30AstraZeneca Stock Rallies on Q3 Earnings Beat, Double-Digit Oncology Growth
BullishOct 30AstraZeneca Launches $1.5 Billion Savings Plan to Fund Drug Pipeline
BullishOct 30AstraZeneca launches overhaul to cut costs by £1.1bn a year
NeutralOct 30
